EX-99.1 2 ex99-1.htm

 

Exhibti 99.1

 

 

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

 

2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026

 

3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix

 

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix

 

Bedford, Mass., March 28, 2024 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.

 

Ted Raad, Chief Executive Officer of Pulmatrix, commented, “Winding down the Phase 2b study for PUR1900, along with other cost-savings measures, is expected to extend Pulmatrix’s cash runway into Q1 2026. We will continue our focus on strategic alternatives that leverage the potential of PUR3100, iSPERSE™ technology and our extended cash resources.”

 

2023 and Recent Program and Corporate Highlights

 

PUR3100

 

  ● In September 2023, Pulmatrix announced the FDA’s acceptance of an IND application for PUR3100 and receipt of a “study may proceed” letter for a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™, will be investigated in patients with acute migraine.
     
  ● The planned Phase 2 trial builds on the Phase 1 trial results, which were published in 2023 and presented at the American Headache Society 65th Annual Meeting in June 2023. Compared to observations of nausea and vomiting in the intravenously (IV) administered DHE dose group, the PUR3100 dose groups showed a lower incidence of nausea and no vomiting. The study also showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels.

 

PUR1800

 

  ● In February 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The results indicated PUR1800 was safe and well tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases. Pulmatrix plans to pursue partnership or other alternatives to monetize or advance PUR1800.

 

 

 

 

 

PUR1900

 

  ● On January 8, 2024, in agreement with its partner Cipla, Pulmatrix announced plans to stop patient enrollment at 8 subjects in the Phase 2b study of PUR1900, effective immediately. PUR1900 is the Company’s inhaled iSPERSE™ formulation of the antifungal drug itraconazole for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need. The decision to stop the study was unrelated to any safety concerns. This study had been ongoing since the first quarter of 2023. The Company expects to complete all Phase 2b activities by the third quarter of 2024.
     
  ● After the study wind down, Pulmatrix will bear no further financial responsibility for the development of PUR1900 and will receive 2% royalties on any potential future net sales by Cipla outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900.

 

Fourth Quarter and Year-End Financial Results

 

Revenues increased $1.2 million to $7.3 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022. The increase is related to higher activity under the Cipla Agreement for PUR1900 during the period.

 

Research and development expenses decreased approximately $2.7 million to $15.5 million for the year ended December 31, 2023, compared to $18.2 million for the year ended December 31, 2022. The decrease was primarily due to decreased spend of $2.7 million in costs related to the Company’s PUR3100 program, $1.0 million of employment costs, and $0.7 million in costs related to the Company’s PUR1800 program, partially offset by an increase of $1.3 million in costs related to the Company’s PUR1900 program and $0.4 million of other operating costs.

 

General and administrative expenses decreased $0.3 million to $6.5 million for the year ended December 31, 2023, compared to $6.8 million for the year ended December 31, 2022. The decrease was primarily due to decreased spend of $0.7 million in employment costs, partially offset by an increase of $0.4 million in legal and professional services costs.

 

The Company’s total cash and cash equivalents balance as of December 31, 2023, was $19.2 million. The Company anticipates that its cash position, based on operational efficiencies and prioritization of spending, is sufficient to fund its operations into the first quarter of 2026.

 

 

 

 

 

PULMATRIX, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

  

December 31, 2023

  

December 31, 2022

 
         
Assets          
Current assets:          
Cash and cash equivalents  $19,173   $35,628 
Restricted cash   -    153 
Accounts receivable   928    1,298 
Prepaid expenses and other current assets   742    1,068 
Total current assets   20,843    38,147 
Property and equipment, net   1,158    235 
Operating lease right-of-use asset   10,309    710 
Long-term restricted cash   1,472    1,472 
Other long-term assets   176    389 
Total assets  $33,958   $40,953 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $1,915   $1,188 
Accrued expenses and other current liabilities   947    1,638 
Operating lease liability   429    857 
Deferred revenue   618    1,339 
Total current liabilities   3,909    5,022 
Deferred revenue, net of current portion   3,727    4,822 
Operating lease liability, net of current portion   8,327    - 
Total liabilities   15,963    9,844 
Stockholders’ equity:          
Preferred stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at December 31, 2023 and December 31, 2022   -    - 
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 and 3,639,185 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively   -    - 
Additional paid-in capital   305,592    304,585 
Accumulated deficit   (287,597)   (273,476)
Total stockholders’ equity   17,995    31,109 
Total liabilities and stockholders’ equity  $33,958   $40,953 

 

 

 

 

 

PULMATRIX, INC.

Consolidated Statements of Operations

(in thousands, except share and per share data)

 

  

Year Ended

December 31,

 
   2023   2022 
Revenues  $7,298   $6,071 
           
Operating expenses          
Research and development   15,518    18,240 
General and administrative   6,520    6,778 
Total operating expenses   22,038    25,018 
Loss from operations   (14,740)   (18,947)
Other income (expense)          
Interest income   867    309 
Other expense, net   (248)   (198)
Total other income (expense), net   619    111 
Net loss  $(14,121)  $(18,836)
Net loss per share attributable to common stockholders – basic and diluted  $(3.87)  $(5.46)
Weighted average common shares outstanding – basic and diluted   3,651,911    3,447,701 

 

 

 

 

 

About Pulmatrix, Inc.

 

Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

 

For more on the Company’s inhaled product candidates please visit: 

https://www.pulmatrix.com/pipeline.html.

 

Forward-Looking Statements

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) endemic on the Company’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Investor Contact:

Timothy McCarthy, CFA

917-679-9282

tim@lifesciadvisors.com